The emm-cluster typing system for group A Streptococcus identifies epidemiologic similarities across the Pacific region

Clinical Infectious Diseases

Volumn 59, Issue 7, 2014, Pages e84-e92

  Baroux, Noémie ^a   D'Ortenzio, Eric ^a   Amédéo, Nathalie ^a   Baker, Ciara ^b,c   Alsuwayyid, Barakat Ali ^c   Dupont Rouzeyrol, Myrielle ^a   O'Connor, Olivia ^a   Steer, Andrew ^b,c,d   Smeesters, Pierre R ^b,c,e  

^a Institut Pasteur de Nouvelle Caledonie Noumea   (New Caledonia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

^e UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Emm cluster; Invasive diseases; Streptococcus pyogenes; Typing; Vaccine

Indexed keywords

STREPTOCOCCUS VACCINE; BACTERIAL ANTIGEN; CARRIER PROTEIN; OUTER MEMBRANE PROTEIN; STREPTOCOCCAL M PROTEIN;

ADOLESCENT; ADULT; ARTICLE; AUSTRALIA; BACTERIAL PHENOMENA AND FUNCTIONS; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CHILD; EMM CLUSTER; FIJI; GENE CLUSTER; GROUP A STREPTOCOCCAL INFECTION; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MOLECULAR EPIDEMIOLOGY; NEW CALEDONIA; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PYOGENES; AGED; CLASSIFICATION; CLUSTER ANALYSIS; FEMALE; GENETICS; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MIDDLE AGED; MOLECULAR TYPING; PRESCHOOL CHILD; STREPTOCOCCAL INFECTIONS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CARRIER PROTEINS; CHILD; CHILD, PRESCHOOL; CLUSTER ANALYSIS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; NEW CALEDONIA; PROSPECTIVE STUDIES; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; YOUNG ADULT;

EID: 84908316201     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu490     Document Type: Article

References (40)

1. Walker MJ, Barnett TC, McArthur JD, et al. Disease manifestations and pathogenic mechanisms of group A Streptococcus. Clin Microbiol Rev 2014;27:264-301.
2. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005;5:685-94.
3. Steer AC, Kado J, Jenney AW, et al. Acute rheumatic fever and rheumatic heart disease in Fiji: prospective surveillance, 2005-2007. Med J Aust 2009;190:133-5.
4. Baroux N, Rouchon B, Huon B, Germain A, Meunier JM, D'Ortenzio E. High prevalence of rheumatic heart disease in schoolchildren detected by echocardiography screening in New Caledonia. J Paediatr Child Health 2013;49:109-14.
5. Le Hello S, Doloy A, Baumann F, et al. Clinical and microbial characteristics of invasive Streptococcus pyogenes disease in New Caledonia, a region in Oceania with a high incidence of acute rheumatic fever. J Clin Microbiol 2010;48:526-30.
6. McMillan DJ, Sanderson-Smith ML, Smeesters PR, Sriprakash KS. Molecular markers for the study of streptococcal epidemiology. Curr Top Microbiol Immunol 2013;368:29-48.
7. Smeesters PR, McMillan DJ, Sriprakash KS. The streptococcal M protein: a highly versatile molecule. Trends Microbiol 2010;18:275-82.
8. Steer AC, Dale JB, Carapetis JR. Progress toward a global group A streptococcal vaccine. Pediatr Infect Dis J 2013;32:180-2.
9. McNeil SA, Halperin SA, Langley JM, et al. Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005;41:1114-22.
10. Facklam RF, Martin DR, Lovgren M, et al. Extension of the Lancefield classification for group A streptococci by addition of 22 new M protein gene sequence types from clinical isolates: emm103 to emm124. Clin Infect Dis 2002;34:28-38.
11. McMillan DJ, Dreze PA, Vu T, et al. Updated model of group A Streptococcus M proteins based on a comprehensive worldwide study. Clin Microbiol Infect 2013;19:E222-9.
12. Smeesters PR, McMillan DJ, Sriprakash KS, Georgousakis MM. Differences among group A Streptococcus epidemiological landscapes: consequences for M protein-based vaccines? Expert Rev Vaccines 2009;8:1705-20.
13. Steer AC, Law I, Matatolu L, Beall BW, Carapetis JR. Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect Dis 2009;9:611-6.
14. Dey N, McMillan DJ, Yarwood PJ, et al. High diversity of group A streptococcal emm types in an Indian community: the need to tailor multivalent vaccines. Clin Infect Dis 2005;40:46-51.
15. Abdissa A, Asrat D, Kronvall G, et al. High diversity of group A streptococcal emm types among healthy schoolchildren in Ethiopia. Clin Infect Dis 2006;42:1362-7.
16. Smeesters PR, Vergison A, Campos D, De Aguiar E, Miendje Deyi VY, Van Melderen L. Differences between Belgian and Brazilian group A Streptococcus epidemiologic landscape. PLoS One 2006;1:e10.
17. Denny FW Jr, Perry WD, Wannamaker LW. Type-specific streptococcal antibody. J Clin Invest 1957;36:1092-100.
18. Lancefield RC. Persistence of type-specific antibodies in man following infection with group A streptococci. J Exp Med 1959;110:271-92.
19. Dale JB, Penfound TA, Chiang EY, Walton WJ. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine 2011;29:8175-8.
20. Dale JB, Penfound TA, Tamboura B, et al. Potential coverage of a multivalent M protein-based group A streptococcal vaccine. Vaccine 2013;31:1576-81.
21. Smeesters PR, Mardulyn P, Vergison A, Leplae R, Van Melderen L. Genetic diversity of group A Streptococcus M protein: implications for typing and vaccine development. Vaccine 2008;26:5835-42.
22. Smeesters PR, Dramaix M, Van Melderen L. The emm-type diversity does not always reflect the M protein genetic diversity-is there a case for designer vaccine against GAS. Vaccine 2010;28:883-5.
23. Sanderson-Smith M, De Oliveira DMP, Guglielmini J, et al. the M Protein Study Group. A systematic and functional classification of Streptococcus pyogenes that serves as a new tool for molecular typing and vaccine development [Epub ahead of print]. J Infect Dis.
24. New Caledonian Institute for Statistics and Economics. New Caledonia facts and figures. Available at: http://www.isee.nc/. Accessed 2 April 2014.
25. Steer AC, Lamagni T, Curtis N, Carapetis JR. Invasive group A streptococcal disease: epidemiology, pathogenesis and management. Drugs 2012;72:1213-27.
26. Grundmann H, Hori S, Tanner G. Determining confidence intervals when measuring genetic diversity and the discriminatory abilities of typing methods for microorganisms. J Clin Microbiol 2001;39:4190-2.
27. Steer AC, Jenney A, Kado J, et al. Prospective surveillance of invasive group A streptococcal disease, Fiji, 2005-2007. Emerg Infect Dis 2009;15:216-22.
28. McDonald MI, Towers RJ, Fagan P, Carapetis JR, Currie BJ. Molecular typing of Streptococcus pyogenes from remote Aboriginal communities where rheumatic fever is common and pyoderma is the predominant streptococcal infection. Epidemiol Infect 2007;135:1398-405.
29. Steer AC, Magor G, Jenney AW, et al. emm and C-repeat region molecular typing of beta-hemolytic streptococci in a tropical country: implications for vaccine development. J Clin Microbiol 2009;47:2502-9.
30. Lamagni TL, Efstratiou A, Vuopio-Varkila J, Jasir A, Schalen C. The epidemiology of severe Streptococcus pyogenes associated disease in Europe. Euro Surveill 2005;10:179-84.
31. Lamagni TL, Neal S, Keshishian C, et al. Severe Streptococcus pyogenes infections, United Kingdom, 2003-2004. Emerg Infect Dis 2008;14:202-9.
32. Erdem G, Mizumoto C, Esaki D, et al. Group A streptococcal isolates temporally associated with acute rheumatic fever in Hawaii: differences from the continental United States. Clin Infect Dis 2007;45:e20-4.
33. Lepoutre A, Doloy A, Bidet P, et al. Epidemiology of invasive Streptococcus pyogenes infections in France in 2007. J Clin Microbiol 2011;49:4094-100.
34. O'Loughlin RE, Roberson A, Cieslak PR, et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis 2007;45:853-62.
35. Safar A, Lennon D, Stewart J, et al. Invasive group A streptococcal infection and vaccine implications, Auckland, New Zealand. Emerg Infect Dis 2011;17:983-9.
36. Papoz L, Barny S, Simon D. Prevalence of diabetes mellitus in New Caledonia: ethnic and urban-rural differences. CALDIA Study Group. CALedonia DIAbetes Mellitus Study. Am J Epidemiol 1996;143:1018-24.
37. Shulman ST, Tanz RR, Dale JB, et al. Seven-year surveillance of North American pediatric group A streptococcal pharyngitis isolates. Clin Infect Dis 2009;49:78-84.
38. De Almeida Torres RS, Fedalto LE, De Almeida Torres RF, Steer AC, Smeesters PR. Group A Streptococcus meningitis in children. Pediatr Infect Dis J 2013;32:110-4.
39. Engel ME, Muhamed B, Whitelaw AC, Musvosvi M, Mayosi BM, Dale JB. Group A streptococcal emm type prevalence among symptomatic children in Cape Town and potential vaccine coverage. Pediatr Infect Dis J 2014;33:208-10.
40. Smeesters PR. Immunity and vaccine development against Streptococcus pyogenes: is emm-typing enough? Proc Belgian Royal Acad Med 2014;3:89-98.